The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.
about
The contribution of resident vascular stem cells to arterial pathologyPhase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors.Hip osteoarthritis and osteoporosis: clinical and histomorphometric considerations.Adult adipose-derived stem cells and breast cancer: a controversial relationship.PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.Molecular profiling of childhood cancer: Biomarkers and novel therapiesThe potential of heparanase as a therapeutic target in cancerAntitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases.The biomolecular basis of adipogenic differentiation of adipose-derived stem cells.Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models.Reconstruction of Alar Nasal Cartilage Defects Using a Tissue Engineering Technique Based on a Combined Use of Autologous Chondrocyte Micrografts and Platelet-rich Plasma: Preliminary Clinical and Instrumental Evaluation.Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?Diabetes and aging: a different phenotypic commitment of circulating and resident stem cells?Comparison of tissue transglutaminase 2 and bone biological markers osteocalcin, osteopontin and sclerostin expression in human osteoporosis and osteoarthritis.
P2860
Q26864886-6C485762-5B88-49C5-A756-0F1A9C327E31Q33420524-1EDFC5CC-708D-4ADB-9A08-FA913CD1D9CFQ33563186-03B05F46-6288-499D-80D3-761809492E76Q33984084-A3FE3E07-42F3-4F8F-B221-60A2AE677F6FQ35832219-37CE53C0-8C5A-4869-BFC3-87C834E38CF4Q36250783-06C295C4-81A2-41F9-A6A6-DB20610430C4Q36452903-AAD78129-6BA3-4143-8531-27132B949235Q37565298-1A2F351D-2702-41DE-B438-D86696375D52Q38205365-3AF1171B-7402-41FA-8A43-E4CAFE58A8C7Q39272645-D1FD2D7B-9245-4638-8FFD-634C5FBA3465Q41677092-B2B83122-71B3-4276-9FEE-26589C7FC850Q47220295-E13FB3B2-BA87-4455-BB65-5F563BCEAB5BQ50554040-1F3B5881-7624-4852-9391-BB13F951C89AQ51673654-07E91046-E4E6-445A-82E9-D1571921C5F3
P2860
The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The curative efficacy of namit ...... d with antiangiogenic effects.
@en
The curative efficacy of namitecan
@nl
type
label
The curative efficacy of namit ...... d with antiangiogenic effects.
@en
The curative efficacy of namitecan
@nl
prefLabel
The curative efficacy of namit ...... d with antiangiogenic effects.
@en
The curative efficacy of namitecan
@nl
P2093
P50
P1476
The curative efficacy of namit ...... d with antiangiogenic effects.
@en
P2093
Angela Maria Di Francesco
Claudio Pisano
Daniela Passeri
Federica Bucci
Franco Zunino
Monica Tortoreto
P304
P356
10.1016/J.BCP.2012.04.005
P407
P50
P577
2012-04-13T00:00:00Z